50 research outputs found
Recommended from our members
Severe Biallelic Loss-of-function Mutations in Nicotinamide Mononucleotide Adenylyltransferase 2 (NMNAT2) in Two Fetuses with Fetal Akinesia Deformation Sequence
The three nicotinamide mononucleotide adenylyltransferase (NMNAT) family members synthesize the electron carrier nicotinamide adenine dinucleotide (NAD+) and are essential for cellular metabolism. In mammalian axons, NMNAT activity appears to be required for axon survival and is predominantly provided by NMNAT2. NMNAT2 has recently been shown to also function as a chaperone to aid in the refolding of misfolded proteins. Nmnat2 deficiency in mice, or in its ortholog dNmnat in Drosophila, results in axon outgrowth and survival defects. Peripheral
nerve axons in NMNAT2-deficient mice fail to extend and innervate
targets, and skeletal muscle is severely underdeveloped. In addition,
removing NMNAT2 from established axons initiates axon death by Wallerian degeneration. We report here on two stillborn siblings with fetal
akinesia deformation sequence (FADS), severely reduced skeletal muscle
mass and hydrops fetalis. Clinical exome sequencing identified compound
heterozygous NMNAT2 variant alleles in both cases. Both protein variants
are incapable of supporting axon survival in mouse primary neuron cultures when overexpressed. In vitro assays demonstrate altered protein
stability and/or defects in NAD+ synthesis and chaperone functions. Thus,
both patient NMNAT2 alleles are null or severely hypo-morphic. These data indicate a previously unknown role for NMNAT2 in human neurological development and provide the first direct molecular evidence to support the involvement of Wallerian degeneration in a human axonal disorder.Funding for the project comes from the NIH (R.W.S. R01NS085023; R.G.Z. R56NS095893), the UK Medical Research Council grant (J.G. MR/N004582/1), the John and Lucille van Geest Foundation (M.C.) and the Taishan Scholar Project of Shandong Province, China (R.G.Z.)
J Med Genet
was previously implicated in periventricular nodular heterotopia (PVNH) in only five individuals and systematic clinical characterisation was not available. The aim of this study is to provide a comprehensive description of the phenotypic and genotypic spectrum of -related neurodevelopmental disorder. We collected detailed phenotypes of an international cohort of individuals (n=17) with variants assembled through the GeneMatcher platform. Missense variants were structurally modelled, and the impact of several were functionally validated. De novo variants (10 missense, 1 frameshift, 1 splice altering resulting in 9 residues insertion) in were identified among 17 unrelated individuals. Detailed phenotypes included intellectual disability (ID), microcephaly, seizures and PVNH. No specific facial characteristics were consistent across all cases, however microretrognathia was common. Various hearing and visual defects were recurrent, and interestingly, some inflammatory features were reported. MRI of the brain frequently showed abnormalities consistent with a neuronal migration disorder. We confirm the role of in an autosomal dominant syndrome with a phenotypic spectrum including severe ID, microcephaly, seizures and PVNH due to impaired neuronal migration
The mouse MC13 mutant is a novel ENU mutation in collagen type II, alpha 1.
Phenotype-driven mutagenesis experiments are a powerful approach to identifying novel alleles in a variety of contexts. The traditional disadvantage of this approach has been the subsequent task of identifying the affected locus in the mutants of interest. Recent advances in bioinformatics and sequencing have reduced the burden of cloning these ENU mutants. Here we report our experience with an ENU mutagenesis experiment and the rapid identification of a mutation in a previously known gene. A combination of mapping the mutation with a high-density SNP panel and a candidate gene approach has identified a mutation in collagen type II, alpha I (Col2a1). Col2a1 has previously been studied in the mouse and our mutant phenotype closely resembles mutations made in the Col2a1 locus
A three-generation breeding scheme to identify recessive ENU mutations affecting organogenesis.
<p>Generation 0 (G0) B6 males are treated with ENU and mated to untreated B6 females to create G1 males. Each G1 establishes an independent pedigree and is mated with FVB females (white) to create G2 females. The resulting G2 females are potential heterozygous carriers of an ENU mutation and obligate heterozygotes at all FVB and B6 SNPs (grey). These G2 females are backcrossed to the G1 and sacrificed to analyze the G3 generation at E18.5. B6 = C57BL/6J; FVB = FVB/NJ.</p
SNP mapping of the MC13 mutants.
<p>A whole-genome SNP panel indicates a region of homozygosity among three MC13 mutant samples. SNPs matching the B6 genome are indicated in red, FVB in blue and heterozygous in yellow. The three mutants show a B6 (ENU-treated) haplotype between SNPs UNC26132263 and B6_15-101391454-S.</p
Sanger sequencing of an ENU mutation at the <i>Col2a1</i> locus.
<p>A heterozygous sample shows the wild type (G) and ENU mutant allele (A). Mutant DNA is homozygous for the ENU variant (A). The ENU mutant locus is boxed and the exon 21 sequence is indicated in blue.</p